Table 1.
Association analysis for four target single-nucleotide polymorphisms and schizophrenia risk, n (%)1
|
SNP
|
Genotype/allele
|
SCZ (n = 443)
|
HC (n = 511)
|
P
value
|
OR (95%CI)
|
HWE test for controls
|
| rs11917047 (PTPRG) | AA | 219 (49.4) | 259 (50.7) | 1.00 (ref) | 0.151 | |
| AG | 183 (41.3) | 200 (39.1) | 0.431 | 1.12 (0.85-1.47) | ||
| GG | 41 (9.3) | 52 (10.2) | 0.713 | 0.92 (0.58-1.45) | ||
| A | 621 (70.1) | 718 (70.3) | 1.00 (ref) | |||
| G | 265 (29.9) | 304 (29.7) | 0.885 | 1.02 (0.83-1.24) | ||
| rs2239681 (IGF2) | AA | 156 (35.2) | 177 (34.6) | 1.00 (ref) | 0.104 | |
| AG | 211 (47.6) | 232 (45.4) | 0.667 | 1.07 (0.80-1.43) | ||
| GG | 76 (17.2) | 102 (20.0) | 0.447 | 0.87 (0.59-1.26) | ||
| A | 523 (59.0) | 586 (57.3) | 1.00 (ref) | |||
| G | 363 (41.0) | 436 (42.7) | 0.567 | 0.95 (0.79-1.14) | ||
| rs3842756 (INSIGF) | CC | 405 (91.4) | 475 (93.0) | 1.00 (ref) | 0.409 | |
| CT | 38 (8.6) | 36 (7.0) | 0.319 | 1.28 (0.79-2.08) | ||
| TT | - | - | - | - | ||
| C | 848 (95.7) | 986 (96.5) | 1.00 (ref) | |||
| T | 38 (4.3) | 36 (3.5) | 0.329 | 1.27 (0.79-2.04) | ||
| rs61955196 (ABCB9) | CC | 157 (35.4) | 202 (39.5) | 1.00 (ref) | 0.513 | |
| CG | 213 (48.1) | 244 (47.7) | 0.297 | 1.16 (0.88-1.55) | ||
| GG | 73 (16.5) | 65 (12.7) | 0.037a | 1.54 (1.03-2.30) | ||
| C | 527 (59.5) | 648 (63.4) | 1.00 (ref) | |||
| G | 359 (40.5) | 374 (36.6) | 0.042a | 1.22 (1.01-1.47) |
a
P < 0.05.
1
Adjusted for gender.
SCZ: Schizophrenia; HC: Healthy control; OR: Odds ratio; HWE: Hardy-Weinberg equilibrium; SNP: Single-nucleotide polymorphism.